.svg){kind=small}
We are using conventional paper CRFs (so there is no worry for clients) which are then remotely entered into a database enabling us to produce tables and listings for safety review within two days of dosing. This is particularly useful in dose escalation studies as meaningful safety reviews can be developed within a very effective time frame.
.avif)
Latest news
Medicines Marketing UK / EU vs US: Why Your Launch Strategy Needs a Continental Divide - Dr Lisa Campbell, Director of Regulatory Strategy
September 12, 2025
A UK CRO’s perspective on planning clinical trials for global success For pharmaceutical companies preparing for global expansion, launching in both the US and EU / UK markets often seems like the natural next step. Yet success in one region does not guarantee success in the other.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
